Published in Oncology Business Week, October 14th, 2007
"The aim of this study was to investigate the role of Cyclin Dependent Kinase Inhibitors ( CDKI) - p21(cip/waf1) and p(27kip1) in TNF-alpha mediated responses in context with p53 and activation of NF-kappa B and Akt...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.